“Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics”. H Zhou, V Arechavala-Gomeza, and A Garanto May 2023 Nucleic Acid Therapeutics

“Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides”. A Goyenvalle, C Jimenez-Mallebrera, W van Roon, S Sewing, A M. Krieg, V Arechavala-Gomeza, and P Andersson February 2023. Nucleic Acid Therapeutics

“Meeting report: oligonucleotide ADME workshop” Steve Hood, David Kenworthy and Jesper Kammersgaard Christensen. December 2022. Xenobiotica

Book: Antisense RNA Design, Delivery, and Analysis. Virginia Arechavala-Gomeza, Alejandro Garanto. 2022. Part of the Methods in Molecular Biology book series (MIMB, volume 2434)

“Delivery of oligonucleotide‐based therapeutics: challenges and opportunities” SM Hammond, A Aartsma-Rus, S Alves, S Even Borgos, R.A.M. Buijsen, R W. J. Collin, G Covello, M A. Denti, L R Desviat, L Echevarría, C Foged, G Gaina, A Garanto, A T. Goyenvalle, M Guzowska, I Holodnuka, DR Jones, S Krause, T Lehto, M Montolio, W Van Roon-Mom and V Arechavala-Gomeza. April 2021 EMBO Mol Medicine

“Joining European Scientific Forces to Face Pandemics”M. H. Vasconcelos, S Alcaro, V Arechavala-Gomeza, J Baumbach, F Borges, T.A.L Brevini, J De Las Rivas, Y Devaux, P Hozak, M M. Keinänen-Toivola, G Lattanzi, T Mohr, M Murovska, B K. Prusty, R A. Quinlan, D Pérez-Sala, C Scheibenbogen, H.H.W. Schmidt, I Silveira, P Tieri, A Tolios, C Riganti December 2020 Trends in Microbiology

“Researcher’s Perceptions on Publishing “Negative” Results and Open Access” L Echevarria, A Malerba, V Arechavala-Gomeza. August 2020 Nucleic Acid Therapeutics

“COST Actions: fostering collaborative research for rare diseases.” LR Desviat, C Jiménez-Mallebrera, A Vallejo-Illarramendi, MD Mayan, G Nogales-Gadea, V Arechavala-Gomeza. November 2019. Lancet Neurology